Previous Statements by JAZZ
» Jazz Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
» Jazz Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
» Jazz Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Jazz Pharmaceuticals's third-quarter results missed analysts' projections.
But we could see more volatility in the market.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.